NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2010 (Six months ended December 31, 2010)
Business Overview: NAI provides private label contract manufacturing services for nutritional supplements and health care products. It also markets branded products under the "Pathway to Healing" line and generates royalty income from its CarnoSyn (beta-alanine) patent estate. The company operates primarily in the United States and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 17.8% to $28.1 million, driven by a 17.8% drop in private label contract manufacturing sales and a 17.5% decline in branded products. The manufacturing decline was attributed to lower volumes from two major customers (Mannatech and NSA International).
• Margin Expansion: Despite lower sales, gross profit margin improved to 19.7% from 16.4% due to a favorable shift in sales mix and reduced overhead expenses.
• Profitability: Net income from continuing operations decreased 5% to $1.766 million. Total net income decreased 12% to $1.766 million, as the prior year included $155,000 in income from discontinued operations (RHL business) which was absent in the current period.
• Liquidity Improvement: Cash and cash equivalents increased significantly to $10.7 million from $4.6 million, supported by strong operating cash flow of $3.2 million.
• Customer Concentration: Revenue concentration from the two largest customers decreased to 73% of total sales from 84% in the prior year.

Guidance, Outlook, and Risks

• Outlook: Management expects net sales and operating income for the third quarter of fiscal 2011 to be lower than the comparable prior year period due to uncertain economic conditions, reduced sales volumes, and lower pricing programs from major customers.
• Litigation Risk: NAI is engaged in patent infringement litigation against Vital Pharmaceutical, Inc. and DNP International Co., Inc. regarding beta-alanine. Litigation expenses were $282,000 for the six months ended Dec 31, 2010, and are expected to increase to approximately $300,000 per quarter for the remainder of fiscal 2011.
• Foreign Exchange: Results may be negatively affected by unfavorable foreign currency exchange activity, specifically a decline in the Euro.
• Strategic Focus: The company plans to re-launch portions of its "Pathway to Healing" product line and increase marketing efforts. It also aims to commercialize its patent estate and improve operational efficiencies.
• Debt Covenants: A new $5.0 million credit facility with Wells Fargo was executed in December 2010. Covenants require maintaining net income after taxes of at least $750,000 on a trailing four-quarter basis and a total liabilities to tangible net worth ratio not exceeding 1.25 to 1.0.

Investor Verification Checklist

• Customer Dependency: Verify the stability of relationships with the top two customers, which accounted for 73% of sales, and the impact of their inventory management programs on future orders.
• Litigation Costs: Monitor the trajectory of legal expenses related to the beta-alanine patent infringement lawsuit, which could impact future profitability.
• Branded Product Recovery: Assess the success of the re-launch strategy for the "Pathway to Healing" product line, which has seen consistent declines.
• Credit Facility Compliance: Confirm continued compliance with the new Wells Fargo credit agreement covenants, specifically the trailing four-quarter net income requirement.
• Foreign Currency Exposure: Evaluate the impact of Euro fluctuations on the European subsidiary (NAIE), which accounts for a significant portion of international sales.